Pattern and spectrum of morphology referrals in breast pathology consultation

Pathology

Volumn 40, Issue 6, 2008, Pages 564-572

  Richelia Jara Lazaro, Ana ^a   Hoon Tan, Puay ^a  

^a SINGAPORE GENERAL HOSPITAL   (Singapore)

Author keywords

Borderline lesions; Breast pathology subspecialty; Pathologic parameters; Second opinion

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; HORMONE RECEPTOR;

ARTICLE; BREAST CARCINOMA; BREAST LESION; CANCER GRADING; CANCER INVASION; CANCER MORPHOLOGY; CANCER SIZE; CARCINOMA IN SITU; CLINICAL EVALUATION; CLINICAL PRACTICE; CONSULTATION; HISTOPATHOLOGY; HUMAN; LABORATORY TEST; PATIENT REFERRAL;

EID: 50449083008     PISSN: 00313025     EISSN: 14653931     Source Type: Journal    
DOI: 10.1080/00313020802320457     Document Type: Article

References (35)

1. Kronz JD, Westra WH, Epstein JI. Mandatory second opinion surgical pathology at a large referral hospital. Cancer 1999; 86: 2426-35.
2. Cook IS, McCormick D, Poller DN. Referrals for second opinion in surgical pathology: implications for management of cancer patients in the UK. Eur J Surg Oncol 2001; 27: 589-94.
3. nd ed. Philadelphia: Lippincott Williams and Wilkins, 2001; xv-xviii.
4. Weidner N. Breast diseases. In: Weidner N. The Difficult Diagnosis in Surgical Pathology. Philadelphia: WB Saunders Company, 1996; 625-79.
5. Leslie KO, Fechner RE, Kempson RL. Second opinions in surgical pathology. Am J Clin Pathol 1996; 106: S58-64.
6. Tan SM, Evans AJ, Lam TP, Cheung KL. How relevant is breast cancer screening in the Asia/Pacific region? Breast 2006; 16: 113-9.
7. Tan PH. Pathology of ductal carcinoma in situ of the breast: a heterogeneous entity in need of greater understanding. Ann Acad Med Singapore 2001; 30: 671-7.
8. Dabbs DJ. Immunocytology, Diagnostic Immunohistochemistry. Philadelphia: Churchill Livingstone, 2006; 546-53, 632-6.
9. Yaziji H, Barry T. Diagnostic immunohistochemistry: what can go wrong? Adv Anat Pathol 2006; 13: 238-45.
10. Wood B, Junckerstorff R, Sterrett G, Frost F, Harvey J, Robbins P. A comparison of immunohistochemical staining for oestrogen receptor, progesterone receptor and HER-2 in breast core biopsies and subsequent excisions. Pathology 2007; 39: 391-5.
11. Ross JS, Fletcher JA. The her-2/neu oncogene in breast cancer: prognostic factor, predictive factor, and target for therapy. Oncologist 1998; 3: 237-52.
12. NHS Cancer Screening Programmes and The Royal College of Pathologists. Pathology Reporting of Breast Disease. London: NHSBSP, 2005; 41-87; NHSBSP Publication no. 58.
13. Ellis IO, Humphreys S, Michell M, Pinder SE, Wells CA, Zakhour HD. Guidelines for breast needle core biopsy handling and reporting in breast screening assessment. J Clin Pathol 2004; 57: 897-902.
14. Going JJ, Mallon EA, Leake RE, Bartlett JM, Gusterson BA. What a clinician needs from the pathologist: evidence-based reporting in breast cancer. Eur J Cancer 2001, 37: S5-17.
15. Anderson TJ, Farzana S, Ellis IO. Implications of pathologist concordance for breast cancer assessments in mammography screening from age 40 years. Hum Pathol 2002; 33: 365-71.
16. Tavassoli FA, Devilee P. Pathology and Genetics: Tumours of the Breast and Female Genital Organs. IARC WHO Classification of Tumours. Lyon: IARC Press, 2003; 9-89.
17. Newman P, Bilous M, Boyages J. Is centralized histopathology review necessary for screen-detected breast lesions? Breast 1999; 8: 320-7.
18. Harvey JM, Sterrett GF, McEvoy S, et al. Pathology reporting of breast cancer: trends in 1989-1999, following the introduction of mammographic screening in Western Australia. Pathology 2005; 37: 341-6.
19. Masood S. The expanding role of pathologists in the diagnosis and management of breast cancer: worldwide excellence in breast pathology program. Breast J 2003; 9 (Suppl): S94-7.
20. Parham DM, Coleman D, Kodikara S, et al. The NHS breast screening programme (pathology EQA: experience in recent years relating to issues involved in individual performance appraisal). J Clin Pathol 2005; 59: 130-7.
21. Vargas HI, Anderson BO, Chopra R, et al. Diagnosis of breast cancer in countries with limited resources. Breast J 2003; 9 (Suppl): S60-6.
22. Collins LC, Connolly JL, Page DL, et al. Diagnostic agreement in the evaluation of image-guided breast core needle biopsies: results from a randomized clinical trial. Am J Surg Pathol 2004; 28: 126-31.
23. Ponsky JL, Gliga L, Reynolds S. Medullary carcinoma of the breast: an association with hormone negative receptors. J Surg Oncol 1984; 25: 76-8.
24. nd ed. Philadelphia: Lippincott Williams and Wilkins, 2001.
25. Putti TC, Pinder SE, Elston CW, Lee AHS, Ellis IO. Breast pathology practice: most common problems in consultation service. Histopathology 2005; 47: 445-57.
26. Lerwill MF. Current practical applications of diagnostic immunohistochemistry in breast pathology. Am J Surg Pathol 2004; 28: 1076-91.
27. Simpson PT, Gale T, Gulford LG, Reis-Filho JS, Lakhani S. The diagnosis and management of pre-invasive breast disease: Pathology of atypical lobular hyperplasia and lobular carcinoma in situ. Breast Cancer Res 2003; 5: 258-62.
28. Koerner F, Maluf H. Uncommon morphologic patterns of lobular neoplasia. Ann Diagn Pathol 1999; 3: 249-59.
29. Tan PH, Tse GMK, Bay BH. Mucinous breast lesions: diagnostic challenges. J Clin Pathol 2008; 61: 11-9.
30. Akhilesh M, Somani A, Tan PH. Biological markers to predict phyllodes tumours in needle core biopsies. Pathology Int 2007; 57 (Suppl 1): A5.
31. Tan PH, Jayabaskar T, Chuah KL, et al. Phyllodes tumours of the breast: the role of pathologic parameters. Am J Clin Pathol 2005; 123: 529-40.
32. Loh HL, Kumarasinghe P, Tan PH. Test and Teach: Recurrent breast lumps in a Chinese woman. Adenomyoepithelioma of the breast. Pathology 2004; 36: 269-72.
33. Foxcroft LM, Evans EB, Porter AJ. The diagnosis of breast cancer in women younger than 40. Breast 2004; 13: 297-306.
34. Fernandopulle SM, Ang PC, Tan PH. Breast carcinoma in women 35 years and younger: a pathological study. Pathology 2006; 38: 219-22.
35. Winchester DP. Breast cancer in young women. Surg Clin North Am 1996; 26: 279-87.